Helpline 07939 046 030

Statement by Michael Fry our Chair of the Board of Trustees

05 May 2020

Dear Friends and Supporters,

I write to you in one of the strangest periods of our lives. At present, a third of the global population is under some form of lockdown, and in the UK, it is unclear how and when restrictions will begin to be relaxed. It is a cliché to say that this is an unprecedented situation. We cannot know what the impact of Covid-19 will be in the medium to long term, except that there will be an impact, and it is likely to be significant generally, and for our charity.

This uncertainty has been devastating for the charity sector, and nearly all charities are reporting huge drops in fundraising income. Many charities find themselves unable to carry out their day-to-day activities, at precisely the time when many beneficiaries are desperate for support and advice.

Despite this, our friends, beneficiaries and supporters have been fantastic. Our community boards have been busy, and I have been really pleased to see the support and advice that we have offered each other, which I am sure has helped to ‘flatten the curve’ for our specialist NF nurses and helpline. The loss of our big fundraising events like the London Marathon and large community initiatives present worries, but our supporters have been amazing and shown such resilience – I have never seen Facebook so full of individual fundraising events from Mel’s Easter Egg head shaving exploits to the 2.6 challenge and other creative lockdown challenges. Please do think of us and consider staging an online fundraiser – people have been really generous, and I have been surprised and touched by the amounts raised so far. Now is also a great time to try to get fit and get prepared to take part in sponsored events for when lockdown is relaxed – you need to register now though for some of them!

I am pleased to report that, for the time being, your charity is in good shape. The Board’s reserves policy has ensured that Nerve Tumours UK has enough money to last through a relatively long period of uncertainty, although this is at the cost of reduced services and staffing. Worse, reliance on the reserves means that there will be a shortfall which we will need to make up in the future.

Karen and the Head Office team reacted swiftly and decisively to the lockdown. I am very grateful to everyone for their willingness during this period and I look forward to Head Office operating normally again as soon as possible. Nerve Tumours UK continues to be available online, providing support via the helpline and funding the Specialist NF Nurse Network. I am sure that I speak for all of us when I express my thanks and appreciation to all the Nerve Tumours UK staff for their extraordinary work and flexibility in the most difficult circumstances. When I clap for our carers each Thursday evening, our staff and specialist advisors are foremost in my mind.

One immediate and regrettable decision the Board has made is to rethink the charity’s strategy for the next five years, a subject which has taken much time and debate over the last year and was nearing publication. The outlook for the charity sector remains bleak, and in the short to medium term the focus of Nerve Tumours UK and the Board must be on maintaining our services and supporting our beneficiaries. Ensuring the long-term stability of the charity must now be our focus, not significant expansion. However, there remains an opportunity to think about the work of the charity and we have issued a short survey to ask you where you think the focus of our activity should be over the next few years.

Lockdown has made it very clear to many in the charity and business sector that there are more efficient ways of working, travel costs (and the environmental impact of that travel) are mostly unnecessary, and video-conferencing is acceptable for social and professional meetings. I would urge you to complete the survey, as we are very keen to hear the views of as many people as possible, whether you live with NF, or if you live with, or care for, someone with NF.

I hope and I trust that you keep well. If, like me, you have school age children, I hope that you manage to keep sane and keep smiling. I appreciate that not everyone has the pleasure/pain of spending this time with family, so please do not allow yourself to be lonely. Come and speak to us – our community forums are a great place to start, and I have found that Zoom chats and streams of text messages can be a helpful temporary replacement for meeting friends and family. There are lots of great resources on the Nerve Tumours UK website and Facebook community pages.

I finish if I may by reminding you that it is almost World NF Day. The Shine a Light campaign is a wonderful opportunity to inform and educate people about NF, and to start conversations with your wider friendship groups. Please do what you can to get stuck in, and let people know all about NF!

My best wishes to you and your loved ones during these challenging times, and please stay safe. As ever, I remain available to all of you, and I would be delighted to hear your thoughts.

Michael Fry
Chair, Nerve Tumours UK

Filter News

Filter by Date
Category
Reset

Disclosing and explaining visible differences - CAR Workshop

Read more about the workshop, featuring additional guidance from Specialist NF Nurse Rebecca Rennison

Read More

Jo Ward’s Avastin Blog

Jo Ward, CEO of NF2 BioSolutions UK, shares a blog about her son Oscar's Avastin journey

Read More

Nigel’s story - Normal is as normal does

Nigel lived a normal life until age 47. The next 20 years took him from NF1 to NF2 to Schwannomatosis to mosaic NF2

Read More

World Mental Health Day 2023

NTUK (as part of the Neurological Alliance) has signed a joint letter aimed at improving access to mental health services

Read More

CAR Research visible difference experiences during recruitment

Research participants required, find out more and take part

Read More

NF Academy 2023 - Ella’s Blog

Ella, who has NF1, attended the week-long 2023 NF Academy in Portugal, meeting young adults with NF from all over Europe

Read More

University of Manchester Research

Read about the latest PHD research, involving Nerve Tumours UK, at the University of Manchester

Read More

New Research Study for Children and Young People with NF1

Find out more about the study and how you can participate here

Read More

Neurofibromatosis Type 2 name change

The new name for Neurofibromatosis Type 2 is NF2-related-Schwannomatosis (NF2)

Read More

Masterclasses in NF: Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome - Prof. Dr. Katharina Wimmer

Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome

Prof. Dr. Katharina Wimmer, Medical University of Innsbruck

Masterclasses in NF: Rare NF1-Associated Tumors in Adults - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: Rare NF1-Associated Tumors in Adults

Eric Legius, MD, PhD, University Hospital Leuven

Prof. Ellen Denayer, University Hospital Leuven

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis - Simon Freeman

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis

Simon Freeman, MPhil FRCS, Manchester Royal Infirmary and Salford Royal Hospital

Masterclasses in NF: NF1 Dermatological Manifestations - Pierre Wolkenstein, Laura Fertitta & Sirkku Peltonen

Masterclasses in NF: NF1 Dermatological Manifestations

Pierre Wolkenstein, MD, PhD, Hopital Henri-Mondor, Paris, France

Laura Fertitta, MD, Hôpital Universitaire Henri Mondor

Sirkku Peltonen, MD, PhD, University of Gothenberg, Sweden

Masterclasses in NF: Breast Cancer in NF1 - Gareth Evans

Masterclasses in NF: Breast Cancer in NF1

Gareth Evans, MD, University of Manchester, UK

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis - David Pang

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis

David Pang, MD, ChB. Guys and St Thomas' Hospital NHS Trust, London

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches - Said Farschtschi

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches

Said Farschtschi, MD, University Medical Center, Hamburg-Eppendorf, Germany

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis

Eric Legius, MD, PHD, University Hospital of Leuven, Belgium

Prof. Ellen Denayer, University Hospital of Leuven, Belgium

NF2 Working Together: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 2: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 1: from a tentative diagnosis and beyond

Understanding  the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

Masterclasses in NF: Surgery in NF2 - Michel Kalamarides & Andrew King

Masterclasses in NF: Surgery in NF2

Michel Kalamarides, MD, PhD, Hôpital Pitié-Salpêtrière, Paris, France

Prof Andrew King, MBBS FRCS FRCS(SN), Salford Royal Hospital, Manchester, United Kingdom. Member of the MAB of Nerve Tumours UK

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches - Shruti Garg, Andre Rietman

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches

Dr Shruti Garg, MBBS, MRCPsych, MMedSci, PhD, Royal Manchester Children’s Hospital, United Kingdom. Member of the MAB of Nerve Tumours UK

Andre Rietman, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis - Susie Henley, Thomas Pletschko & Verena Rosenmayr

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis

Susie Henley, DClinPsy, PhD, Guy’s and St Thomas’ NHS Foundation Trust, London UK

Thomas Pletschko, PhD, Medical University of Vienna, Austria

Verena Rosenmayr, Clinical Psychologist, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Pediatric Management - Rianne Oostenbrink

Masterclasses in NF: NF1 Pediatric Management

Rianne Oostenbrink, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond - Amedeo Azizi

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond

Amedeo Azizi, MD, PhD, Head of the Paediatric Neurofibromatosis Program and Paediatric Neuro-Oncology Program, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Orthopedic Manifestations - Eric Legius and Christophe Glorion

Masterclasses in NF: NF1 Orthopedic Manifestations

Eric Legius, MD, PhD. Head of Clinical Genetics Department of the University Hospital Leuven, Belgium

Christophe Glorion, MD, PhD, Department of Paediatric Orthopedic and Traumatologic Surgery, Hopital Necker-Enfants Malades, Paris, France. 

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours - Rosalie Ferner and Viktor-Felix Mautner

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK

Viktor-Felix Mautner, MD, PhD. University Medical Centre in Hamburg-Eppendorf, Germany. Head of NF Outpatient Department

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas - Pierre Wolkenstein and Sirkku Peltonen

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas

Pierre Wolkenstein, MD, PhD. Hopital Henri-Mondor, Paris, France. Head of the Department of Dermatology

Sirkku Peltonen MD, PhD. University of Gothenberg, Sweden. Professor of Dermatology

INFER (International NF Educational Resources) is a series of online educational lectures for medical professionals by leading neurofibromatosis experts. The Masterclasses take place online approximately once a month, each on a different topic, and include real-time interaction between the expert presenter and the participants. The presentations are conducted in English, with real-time audio interpretation available in 6 additional languages: French, German, Italian, Portuguese, Russian, and Spanish. A recording of each INFER masterclass is then be made available online in each language for those who could not attend an event. INFER is an initiative of Children’s Tumor Foundation Europe, supported by an educational grant from AstraZeneca. https://ctfeurope.org/research/masterclasses-in-nf

BPNA Keynote Lecture - Prof Rosalie Ferner - Neurofibromatosis 1 in the 21st Century

‘Neurofibromatosis 1 in the 21st Century’

Keynote Lecture at the 48th British Paediatric Neurology Association Annual Scientific Meeting on 21st January 2022

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK